멀티플렉스 검사용 시약 시장 규모, 점유율, 동향 분석 보고서 : 종류별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Multiplex Testing Reagents Market Summary

The global multiplex testing reagents market size was estimated at USD 1.42 billion in 2024 and is expected to reach USD 4.15 billion by 2033, growing at a CAGR of 13.08% from 2025 to 2033. Multiplex testing reagents enable the simultaneous detection of multiple analytes in a single test, offering higher efficiency and cost-effectiveness compared to conventional single-target assays.

Their ability to provide comprehensive diagnostic data in shorter timeframes has driven adoption across clinical, research, and pharmaceutical applications. The market's growth is further fueled by the increasing demand for personalized medicine, where rapid and precise detection of multiple biomarkers is critical for tailoring treatment strategies. Technological advancements in assay design, automation, and detection platforms have also enhanced the reliability and throughput of multiplex testing, making it an attractive choice for laboratories aiming to optimize workflow while minimizing sample volume and operational costs.

A primary factor driving the growth of multiplex testing reagents is the rising prevalence of chronic diseases and infectious conditions worldwide. Chronic illnesses such as cardiovascular disorders, cancer, autoimmune diseases, and metabolic syndromes often involve multiple biomarkers, making multiplex assays an efficient tool for comprehensive monitoring and diagnosis. In addition, the global burden of infectious diseases, including viral, bacterial, and emerging pathogens, has increased the need for high-throughput diagnostic solutions capable of detecting multiple pathogens simultaneously. Multiplex reagents allow clinicians to screen for co-infections and identify pathogen profiles in a single test, reducing diagnostic delays. This is particularly important in public health scenarios where early detection can prevent outbreaks. Consequently, growing disease prevalence directly correlates with increased adoption of multiplex testing reagents, thereby driving market expansion.

Technological innovation is a key driver of market growth for multiplex testing reagents. Advanced assay platforms, such as bead-based flow cytometry, microarrays, and next-generation sequencing-compatible reagents, have enhanced the sensitivity, specificity, and throughput of multiplex testing. Automation and integration with laboratory information systems have further streamlined workflows, allowing laboratories to process larger sample volumes with reduced human error. Novel reagent chemistries and labeling techniques have improved the detection of low-abundance biomarkers, expanding clinical and research applications. In addition, miniaturization and microfluidic technologies have enabled point-of-care multiplex testing, bringing laboratory-grade analysis closer to patients. These technological improvements not only improve diagnostic accuracy but also reduce turnaround time and costs, making multiplex testing reagents increasingly attractive for hospitals, diagnostic laboratories, and research institutions globally.

Global Multiplex Testing Reagents Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global multiplex testing reagents market report based on type, application, end use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Biotin-based Reagents
  • Biotinylated Antibodies
  • Biotinylated Probes/primers
  • Biotin-tagged Proteins/enzymes
• Streptavidin-based Reagents
  • Streptavidin-conjugated Beads/microspheres
  • Streptavidin-conjugated Enzymes & Fluorophores
  • Recombinant Streptavidin Variants (engineered for higher stability)
  • Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Autoimmune Disease Diagnostics
• Infectious Disease Diagnostics
• Oncology
• Allergy Testing
• Research & Translational Medicine
• Drug Discovery & Development
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical & Diagnostic Laboratories
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Multiplex Testing Reagents Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Type Segment
    • 1.1.1.2. Application Method
    • 1.1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Multiplex Testing Reagents Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Type
• 2.3. Application Snapshot
• 2.4. End Use Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Multiplex Testing Reagents Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Growing demand for precision diagnostics and personalized medicine
  • 3.4.2. Technological advancements in multiplex assay platforms
  • 3.4.3. Rising r&d investments in drug discovery and translational research
• 3.5. Market Restraint Analysis
  • 3.5.1. High cost of multiplex assay reagents and equipment
  • 3.5.2. Complex validation and standardization challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Multiplex Testing Reagents Market: Type Estimates & Trend Analysis

• 4.1. Multiplex Testing Reagents Market: Type Movement Analysis
• 4.2. Multiplex Testing Reagents Market by Type Outlook (USD Million)
• 4.3. Biotin-based Reagents
  • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.2. Biotinylated Antibodies
    • 4.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.3. Biotinylated Probes/primers
    • 4.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.4. Biotin-tagged Proteins/enzymes
    • 4.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Streptavidin-based Reagents
  • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Streptavidin-conjugated Beads/microspheres
    • 4.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Streptavidin-conjugated Enzymes & Fluorophores
    • 4.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Recombinant Streptavidin Variants (engineered for higher stability)
    • 4.4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Others
  • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Multiplex Testing Reagents Market: Application Method Estimates & Trend Analysis

• 5.1. Multiplex Testing Reagents Market: Application Method Movement Analysis
• 5.2. Multiplex Testing Reagents Market by Application Outlook (USD Million)
• 5.3. Autoimmune Disease Diagnostics
  • 5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Infectious Disease Diagnostics
  • 5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Oncology
  • 5.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Allergy Testing
  • 5.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Research & Translational Medicine
  • 5.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Drug Discovery & Development
  • 5.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Multiplex Testing Reagents Market: End Use Estimates & Trend Analysis

• 6.1. Multiplex Testing Reagents Market: End Use Movement Analysis
• 6.2. Multiplex Testing Reagents Market by End Use Outlook (USD Million)
• 6.3. Clinical & Diagnostic Laboratories
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Pharmaceutical & Biotechnology Companies
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Contract Research Organizations (CROs)
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Academic & Research Institutes
  • 6.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Multiplex Testing Reagents Market: Regional Business Analysis

• 7.1. Regional Market Snapshot
• 7.2. North America
  • 7.2.1. North America Multiplex Testing Reagents Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.2.2.2. Key Country Dynamics
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Reimbursement Scenario
    • 7.2.2.5. Competitive Scenario
  • 7.2.3. Canada
    • 7.2.3.1. Canada Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.2.3.2. Key Country Dynamics
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Reimbursement Scenario
    • 7.2.3.5. Competitive Scenario
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.2.4.2. Key Country Dynamics
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Reimbursement Scenario
    • 7.2.4.5. Competitive Scenario
• 7.3. Europe
  • 7.3.1. Europe Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.3.2.2. Key Country Dynamics
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. Competitive Scenario
  • 7.3.3. Germany
    • 7.3.3.1. Germany Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.3.3.2. Key Country Dynamics
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Competitive Scenario
  • 7.3.4. Spain
    • 7.3.4.1. Spain Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.3.4.2. Key Country Dynamics
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. Competitive Scenario
  • 7.3.5. France
    • 7.3.5.1. France Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.3.5.2. Key Country Dynamics
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Reimbursement Scenario
    • 7.3.5.5. Competitive Scenario
  • 7.3.6. Italy
    • 7.3.6.1. Italy Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.3.6.2. Key Country Dynamics
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Reimbursement Scenario
    • 7.3.6.5. Competitive Scenario
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.3.7.2. Key Country Dynamics
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Reimbursement Scenario
    • 7.3.7.5. Competitive Scenario
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.3.8.2. Key Country Dynamics
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Reimbursement Scenario
    • 7.3.8.5. Competitive Scenario
  • 7.3.9. Norway
    • 7.3.9.1. Norway Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.3.9.2. Key Country Dynamics
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Reimbursement Scenario
    • 7.3.9.5. Competitive Scenario
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.4.2.2. Key Country Dynamics
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. Competitive Scenario
  • 7.4.3. China
    • 7.4.3.1. China Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.4.3.2. Key Country Dynamics
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. Competitive Scenario
  • 7.4.4. India
    • 7.4.4.1. India Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.4.4.2. Key Country Dynamics
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. Competitive Scenario
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.4.5.2. Key Country Dynamics
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. Competitive Scenario
  • 7.4.6. Thailand
    • 7.4.6.1. Thailand Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.4.6.2. Key Country Dynamics
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Reimbursement Scenario
    • 7.4.6.5. Competitive Scenario
  • 7.4.7. Australia
    • 7.4.7.1. Australia Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.4.7.2. Key Country Dynamics
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. Competitive Scenario
• 7.5. Latin America
  • 7.5.1. Latin America Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.5.2.2. Key Country Dynamics
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Competitive Scenario
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.5.3.2. Key Country Dynamics
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Competitive Scenario
• 7.6. Middle East & Africa
  • 7.6.1. Middle East & Africa Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.6.2.2. Key Country Dynamics
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Competitive Scenario
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.6.3.2. Key Country Dynamics
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Competitive Scenario
  • 7.6.4. UAE
    • 7.6.4.1. UAE Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.6.4.2. Key Country Dynamics
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. Competitive Scenario
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Multiplex Testing Reagents Market, 2021 - 2033 (USD Million)
    • 7.6.5.2. Key Country Dynamics
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
  • 8.2.1. New Product Launch
  • 8.2.2. Partnerships
  • 8.2.3. Acquisition
  • 8.2.4. Collaboration
  • 8.2.5. Funding
• 8.3. Key Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Company Profiles
  • 8.5.1. Luminex Corporation
    • 8.5.1.1. Company Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Bio-Rad Laboratories, Inc.
    • 8.5.2.1. Company Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Abcam plc.
    • 8.5.3.1. Company Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Seegene Inc.
    • 8.5.4.1. Company Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Merck KGaA
    • 8.5.5.1. Company Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Illumina, Inc.
    • 8.5.6.1. Company Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Promega Connections
    • 8.5.7.1. Company Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. QIAGEN N.V.
    • 8.5.8.1. Company Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Thermo Fisher Scientific
    • 8.5.9.1. Company Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. PerkinElmer Inc.
    • 8.5.10.1. Company Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. Bio-Techne Corporation
    • 8.5.11.1. Company Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives
  • 8.5.12. BD
    • 8.5.12.1. Company Overview
    • 8.5.12.2. Financial Performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic Initiatives